Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppression Versus Medical Therapy for UN-explained Low Ejection Fraction and VT
NCT06635863Phase 4Enrolling by invitation
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of prednisone in ventricular tachycardia (VT) and Non-Ischaemic Cardiomyopathy (NICM) (2 arms). Primary endpoints: Burden of ventricular arrhythmias at 12 months, Change in left ventricular ejection fraction at 12 months and 2 more. Started Nov 2024; status: enrolling by invitation.
02
Drugs
prednisone
03
Conditions
ventricular tachycardia (VT)Non-Ischaemic Cardiomyopathy (NICM)
Beyond the preview
Go deeper on NCT06635863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635863.